Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Retatrutide is an experimental triple-agonist weight-loss and diabetes drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors
This facilitates the nuclear translocation of YAP1, subsequently triggering the transcription of ALDH1A1
Total Estimated Monthly Cost: If you choose compounded semaglutide: approximately $150 per month ($75 medication + $74.99 program fee) If you choose compounded tirzepatide: approximately $208 per month ($133 medication + $74.99 program fee) These are starting prices per the company's published FAQ
With the compounded GLP-1 market becoming increasingly competitive, pharmacies differentiate their products by adding value-added ingredients
Per FTC guidance and EU Omnibus Directive standards for buyers in the EU, comparison "before" prices should reflect actual reference pricing - verify directly with the brand if this is relevant to your purchase decision
This allows for comprehensive medication review, assessment of potential interactions with other medications, and appropriate monitoring
US$ 28.61
US$ 29.32
US$ 27.84
US$ 29.32
US$ 26.29
US$ 21.13
US$ 27.19
